These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35877249)

  • 1. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
    Yao L; Jia G; Lu L; Ma W
    Curr Oncol; 2022 Jul; 29(7):4902-4913. PubMed ID: 35877249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy.
    Saraiva DP; Jacinto A; Borralho P; Braga S; Cabral MG
    Front Immunol; 2018; 9():2605. PubMed ID: 30555458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer.
    Eryilmaz MK; Mutlu H; Ünal B; Salim DK; Musri FY; Coşkun HŞ
    J Cancer Res Ther; 2018; 14(3):619-624. PubMed ID: 29893329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
    Liang Y; Lü W; Zhang X; Lü B
    Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
    Cerbelli B; Botticelli A; Pisano A; Pernazza A; Campagna D; De Luca A; Ascierto PA; Pignataro MG; Pelullo M; Rocca CD; Marchetti P; Fortunato L; Costarelli L; d'Amati G
    Virchows Arch; 2020 Apr; 476(4):569-576. PubMed ID: 31853625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
    D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
    Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
    Zhang L; Wang XI; Zhang S
    Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    Geng SK; Fu SM; Ma SH; Fu YP; Zhang HW
    BMC Cancer; 2021 Jan; 21(1):68. PubMed ID: 33446143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis.
    Yokotani T; Ikeda N; Hirao T; Tanaka Y; Morita K; Fujii T; Ohbayashi C; Nakamura T; Kobayashi T; Sho M
    Surg Today; 2021 Apr; 51(4):595-604. PubMed ID: 33052489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
    Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Nuciforo P; Pascual T; Cortés J; Llombart-Cussac A; Fasani R; Paré L; Oliveira M; Galvan P; Martínez N; Bermejo B; Vidal M; Pernas S; López R; Muñoz M; Garau I; Manso L; Alarcón J; Martínez E; Rodrik-Outmezguine V; Brase JC; Villagrasa P; Prat A; Holgado E
    Ann Oncol; 2018 Jan; 29(1):170-177. PubMed ID: 29045543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting.
    Khoury T; Aljabab S; Yao S; Ambrosone C; Omilian A; Attwood K; Ji W; Gandhi S
    Breast Cancer Res Treat; 2022 Aug; 194(3):531-540. PubMed ID: 35716216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
    Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
    Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F
    Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Sinn BV; Weber KE; Schmitt WD; Fasching PA; Symmans WF; Blohmer JU; Karn T; Taube ET; Klauschen F; Marmé F; Schem C; Stickeler E; Ataseven B; Huober J; von Minckwitz G; Seliger B; Denkert C; Loibl S
    Breast Cancer Res; 2019 Dec; 21(1):142. PubMed ID: 31829264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis.
    Maskey N; Li K; Hu M; Xu Z; Peng C; Yu F; Cao H; Chen J; Li Y; Yang G
    Tumour Biol; 2014 Dec; 35(12):11837-43. PubMed ID: 25260881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy.
    Raphael J; Nofech-Mozes S; Paramsothy T; Li N; Gandhi S
    Pathol Oncol Res; 2019 Oct; 25(4):1341-1347. PubMed ID: 29222623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.